Tag Archives: ovarian cancer

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Posted on 22, January 2018 by

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release →

Posted in Healthcare, Pharma & Biotech, United Kingdom

Tagged , , , , , , , ,

Ovarian Cancer: Merck, Pfizer initiate Phase III study JAVELIN Ovarian 100

Posted on 7, July 2016 by

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women Darmstadt, Germany and New York, US, 07-Jul-2016 … Read the full press release →

Posted in Germany, Healthcare, Pharma & Biotech, Science

Tagged , , ,

Roche announced EU approved Avastin (bevacizumab) as treatment for women with recurrent ovarian cancer resistant to platinum-containing chemotherapy

Posted on 13, August 2014 by

First new treatment option for women in Europe in more than 15 years for most difficult to treat form of ovarian cancer BASEL, 13-8-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EU) approved the … Read the full press release →

Posted in Healthcare, Pharma & Biotech, Switzerland

Tagged , , ,